Leflunomide Tablet
Product Images NDC 46708-437

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 46708-437). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Leflunomide 10mg)

Label for Leflunomide Tablets USP, 10 mg strength, oral tablet form. The label includes NDC 46708-436-30, indicates the package contains 30 tablets, and is labeled Rx only. Manufactured by Alembic Pharmaceuticals Limited. Storage and tamper-evidence warnings are also included.*

FDA Label Image

30's Bottle Pack (Leflunomide 20mg)

Leflunomide Tablets USP 20 mg oral tablets label from Alembic Pharmaceuticals Limited. The label indicates a package of 30 film-coated tablets with NDC 46708-437-30, includes storage instructions, warnings, and manufacturing details. The label features a barcode and dosage strength prominently.*

FDA Label Image

Figure 1 (Leflunomide Figure1)

Bar chart showing the percentage of ACR 20 responders at the endpoint across three clinical trials with Leflunomide, Methotrexate, Placebo, and Sulfasalazine. The trials measure response rates at 6 or 12 months, indicating comparative efficacy percentages for each treatment group.*

FDA Label Image

Figure 2 (Leflunomide Figure2)

A line chart titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders on the y-axis and time in months on the x-axis from 0 to 12 months. The chart includes data lines for three groups: placebo (PL), methotrexate (MTX), and leflunomide (LEF), illustrating response rates over time with LEF showing high response percentages compared to PL and MTX.*

FDA Label Image

Figure 3 (Leflunomide Figure3)

A bar chart titled 'Change in Sharp Score' showing disease progression over three clinical trials of varying durations (6 to 12 months). The x-axis groups data by Trial 1, Trial 2, and Trial 3 with bars marked for Leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P). Numeric values are displayed above each bar, indicating different Sharp score changes per treatment group. The y-axis denotes progression scores from -10 to +8 with progression direction indicated downward.*

FDA Label Image

Figure 4 (Leflunomide Figure4)

A bar chart titled "Change in Functional Ability Measure" showing data from three clinical trials measuring improvement as per the HAQ Disability Index. The y-axis represents improvement from 0 to -0.6. Bars represent treatments Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) with various improvements noted for each in Trials 1 (12 months), 2 (6 months), and 3 (12 months).*

FDA Label Image

Structure (Leflunomide Metabolite)

Chemical structure of Leflunomide showing its molecular framework, including a trifluoromethyl-substituted aromatic ring and functional groups such as amide, keto, hydroxyl, and nitrile moieties.*

FDA Label Image

Structure (Leflunomide Structure)

Chemical structure of Leflunomide, showing its molecular arrangement with a trifluoromethyl group attached to a phenyl ring, an amide linkage, and a substituted isoxazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.